Investment Banking For Life Sciences & Healthcare

BOUTIQUE BANK. GLOBAL REACH.

Our Sole Focus is Life Sciences & Healthcare

WaveEdge Capital is an independent M&A advisory firm that helps companies to raise capital or to sell themselves. We work exclusively with companies in the pharmaceutical services, healthcare services, digital health and life sciences spaces.

Our senior team has facilitated deals worth billions of dollars in aggregate transaction value and has extensive relationships with large corporate buyers and private equity investors.

Let us help you construct and facilitate an innovative and lucrative transaction solution for your business.

OUR SYSTEMATIC APPROACH

We help you determine the optimal path and outcome for your company by:

Developing a compelling value proposition for potential acquirers, investors and partners;
Educating the market to heighten interest and widen the reach beyond the obvious and traditional; and
Pressure-testing assumptions and bringing deep financial, valuation, structuring and negotiating skills to bear, all to increase the value of your transaction.

OUR DIFFERENCE

Speaking the language of the target audience takes more than investment banking skills. Our systematic approach is based on three decades of life sciences, healthcare and transaction experience.

Pharma Services

The pharma services market continues to grow rapidly as large pharma oustources a greater percentage of its R&D and manufacturing, and as venture money continues to pour into the biotech space. This is resulting in an unprecedented opportunity for pharma services companies to grow or sell themselves.

WaveEdge advises companies serving the life sciences industry with a deep understanding of the drug and medical device development process. Whether you'd like to raise additional private capital to grow your company or plan an exit strategy, we'd be delighted to speak with you.

Companies we work with in this space include:

• CROs and CMOs/CDMOs
• Clinical & regulatory consulting firms
• Pharma packaging and distribution companies
• Life sciences equipment, diagnostic and tool companies
• Precision medicine and companion diagnostics
• Outsourced commercialization services / CSOs

LARGE NETWORK OF BUYERS AND INVESTORS

We help your company gain access to the right type of buyers to sell your business or raise capital to expand your business, whether building up your sales and marketing team, launching a new product or expanding into new territories. We can connect you to more than 100 private equity firms interested in investing in or buying companies in the pharma services space.

EXPERIENCED FINANCIAL AND HEALTHCARE TEAM

The WaveEdge team combines a deep domain expertise in life sciences and health with 30 years of investment banking and strategic advisory experience. Our diverse background in finance, clinical development and pharma services gives our clients a significant advantage in positioning themselves to the right buyers and investors for an optimal outcome.

Healthcare Services

We are in a particularly opportune time for healthcare services companies:

• Demographic shift resulting in an aging population with a higher prevalence of chronic diseases
• Regulatory and reimbursement shift to value-based care
• Technology shift to leverage healthcare services companies at unprecedented levels

As a result, we see in our large network of private equity and family office firms a strong interest in investing in the healthcare services space.

WaveEdge advises medical groups, clinics, pharmacies and other healthcare services companies to help them sell their company, raise capital or acquire another company. As preferred M&A advisor to America’s Physician Groups (APG) and frequent speakers on healthcare service company valuations and the M&A process, we have deep expertise in this space.

Companies we work with in this space include:

• Clinics: imaging, dialysis, behavioral health, urgent care and other specialist medical centers
• Healthcare technology & digital health
• Home healthcare and hospice groups
• Medical groups: physician practices (both primary care and specialist), dental practices, MSOs
• Medical staffing services

LARGE NETWORK OF BUYERS AND INVESTORS

EXPERIENCED FINANCIAL AND HEALTHCARE TEAM

The WaveEdge team combines a deep domain expertise in life sciences and health with 30 years of investment banking and strategic advisory experience. Our diverse background in finance and healthcare services gives our clients a significant advantage in positioning themselves to the right buyers and investors for an optimal outcome.

Digital Health

Delivery of healthcare is rapidly transforming as the worldwide population lives longer and the cost of managing chronic, age-related disease skyrockets. Innovative mobile, cloud-based information and sensing technologies combined with massive government incentives are creating a more connected, data-focused, outcomes-based healthcare system.

EXPERIENCED FINANCIAL AND HEALTHCARE TEAM

With one bank, you gain access to three critical areas for digital health: healthcare, technology and banking. We have advised companies in multiple areas across the digital health space, such as biosensors, remote monitoring, wearables and patient adherence. Our clinical knowledge into specific disease states and provider/patient interactions is significant.

As advisory board members of Launchpad Digital Health fund and speakers at multiple digital health conferences, we can provide perspective for founders and assist with helpful introductions. And we are grounded with a strong foundation of 30 years in investment banking and financial advisory services.

Therapeutics, Devices & Diagnostics

Biopharmaceutical, medical device and diagnostics companies operate in a dynamic environment with a broad set of challenges. Capital constraints, pricing and reimbursement shifts, and changing regulatory guidelines are just some of the challenges our clients face. Despite this, the life sciences space is at one of the most exciting points in its history, as significant capital continues to fund major breakthroughs in science and as demographic shifts result in an older population more dependent on the benefits that life science technology can provide.

DEEP EXPERTISE IN LIFE SCIENCES

The WaveEdge team has deep expertise and a strong network across the biopharmaceutical landscape. We have founded, operated and advised biopharma, device and diagnostics companies as CEOs, board members, strategy consultants and bankers. We have spent years advising both large pharma and VC-backed biotech companies on transaction strategy and valuation.

STRONG TRACK RECORD OF SUCCESSFUL TRANSACTIONS

WaveEdge team members have advised and guided many companies through successful capital raises, strategic licensing and partnerships and highly successful M&A transactions.

ACHIEVING OPTIMAL RESULTS FOR OUR CLIENTS

Team Member Experience

A WORLD CLASS TEAM. A POWERFUL BLEND OF PERSPECTIVES.

Our Team

Jeff Karan

Managing Partner

💻jeff.karan@waveedgecap.com

📞 (650) 851-4639

Jeff brings over 30 years of investment banking and corporate advisory experience to WaveEdge Capital. He started his career in 1980 at Morgan Stanley and later moved to Goldman Sachs, all in NYC. He has participated in over $5B in investment banking transactions and has extensive knowledge of the capital raising and M&A process. In addition, Jeff has advised clients on corporate strategy, business valuation, and a wide range of strategic partnership structures.

Jeff holds an MBA from Dartmouth’s Amos Tuck School of Business Administration (Tuck Scholar) and a BA in Economics from Dartmouth College. He later received an MA in Comparative Philosophy and Religion on the west coast. Jeff was recently named to the Connected Health Conference Advisory Board 2017, a merger of the Partners Connected Health Symposium and the Personal Connected Health Alliance’s Connected Health Conference (formerly the mHealth Summit). Jeff is an avid skier and cyclist and is passionate about philosophy, the history of ideas, poker theory, and global economic analysis. (FINRA 7, 24, 63, 79, 99)

John Selig

Managing Partner

💻 john.selig@waveedgecap.com

📞 (650) 353-7286

John advises healthcare and life sciences companies on M&A, licensing and financial strategy. He also frequently speaks on topics in valuation, deal term benchmarking, and strategy.

Prior to joining WaveEdge, John was a Managing Director at Woodside Capital Partners, a boutique investment bank, where he co-founded and co-led the healthcare and life sciences group. Previously, he was a Principal at Keelin Reeds, a healthcare and life sciences management consulting firm, where he advised dozens of VC-backed and small to mid-cap biopharmaceutical, medical device, and diagnostics companies on M&A, licensing strategies, portfolio management, valuation and strategic direction. He was also an advisor at Strategic Decisions Group (SDG), a global management consulting firm, where he advised many of the top 20 pharmaceutical and medical device companies, as well as Fortune 500 companies in other industries on valuation, business strategy and M&A.

Prior to consulting, John was an attorney with Weil, Gotshal and Manges LLP where he focused on M&A and corporate finance. John holds a JD from Stanford Law School, where he was an Associate Editor of the Law Review, and a BA, magna cum laude, from Brown University, where he was a member of Phi Beta Kappa. (FINRA 24, 79, 63)

Juliesta Sylvester

Managing Director

Juliesta brings 20 years of experience leading data analytics startups and partnering with healthcare, biotechnology and pharmaceutical companies to advise clients on capital raising, portfolio enrichment, and M&A. At WaveEdge, she specializes in growth-oriented security transactions within the therapeutic manufacturing, molecular diagnostics, digital health, and healthcare services industries.

Prior to joining WaveEdge, Juliesta was Managing Director at Woodside Capital Partners, a technology investment bank in Silicon Valley. She has advised private equity firms, such as Carlyle, for buy-side diligence and early stage, Sand Hill Road-backed tech companies, such as OpenTrons, for strategic planning. Previously, she was Head of both the Global Data and Innovation & Acquisition divisions at Diaceutics, where she vetted tech companies for acquisition, assessed data risks, and spearheaded efforts that transformed the privately-owned consulting company into a publicly traded technology company on the LSE. Juliesta closed asset transactions with multiple companies, primarily focused on collections of HIPAA and GDPR-compliant clinical data. She led product development initiatives with Janssen, Merck, BioRad, Luminex, Molecular Assemblies, and SoluLink, which were focused on diagnostic and therapeutic design and commercialization. For 7 years, Juliesta also co-invested with Beacon Value Partners focusing on small-cap biotech companies navigating FDA approval.

Juliesta has a Ph.D. in Biochemistry & Molecular Biology and BA, both from the University of Chicago. She completed postdoctoral product innovation partnerships at the Massachusetts Institute of Technology (MIT) and the Scripps Research Institute (TSRI). (Series 79,63)

Michael Mischke-Reeds

Business Advisor

Michael brings 25 years of experience as a management consultant and biotech executive. He has led or advised on over 15 closed life sciences transactions, including partnerships, M&A, and investment. His expertise includes corporate, therapeutic area, R&D portfolio, commercial, and business development strategy for dozens of life sciences companies. A recognized expert in life sciences asset valuation, he has served as an expert witness on company valuation and partnership deal terms in multiple litigation cases and regularly presents at major industry conferences.

Prior to WaveEdge, Michael was a Managing Partner at Keelin Reeds Partners, a life sciences-focused management consulting firm. He led Portfolio Strategy and Business Development at Nurix Therapeutics and led Business Development and Strategy at Emulate Therapeutics.

Michael studied biology and management science at Stanford University and has a Master’s degree in Psychology. He is a Fellow in the Society of Decision Professionals.

Rose Maljanian

Managing Director

Rose serves as Managing Director and focuses on healthcare services. She is also CEO of HealthCAWS, a privately held healthcare services company focused on strategic advisory, M&A and platform tools that impact behaviors and outcomes including as Operating Partner for Pharos Capital and multiple privately held company advisory boards. Rose is an accomplished senior executive having held executive leadership positions at Hartford Hospital, Humana and Magellan Health Services, driving innovation, positive organizational change and results for over 35 years in the healthcare industry. She was a member of Magellan Health’s mergers and acquisition team focused on product and market positioning diligence. She is Chairman of the Board and Chair Emeritus for the Population Health Alliance. She holds a BS in Nursing from St. Joseph College, was critical care certified, and holds an MBA from Rensselaer Polytechnic Institute.

Joseph C. Kvedar, MD

Business Advisor

Vice President, Connected Health, Partners HealthCare

Joseph C. Kvedar, MD, is creating a new model of healthcare delivery by leveraging personal connected health technologies and remote monitoring tools to better manage chronic conditions, maintain health and wellness, and improve adherence, engagement and clinical outcomes. He is the author of The Internet of Healthy Things, describing how everyday objects will capture and use real-time biometric data to ultimately change behavior to improve our health. Dr. Kvedar created Wellocracy, a leading source of impartial, easy-to-understand information to encourage the sustained use of personal “self-health” technologies.

He is internationally recognized for his leadership and vision in the field of connected health, and has authored over 100 publications on the subject; the popular cHealth Blog provides his insights and vision for connected health. Dr. Kvedar serves as a strategic advisor at Qualcomm Life, Puretech Ventures and BD Technologies, and is a mentor at Blueprint Health, providing guidance and insight to developing companies. Dr. Kvedar is also a mentor at the Harvard Innovation Lab and serves as a judge for its President’s Challenge for Entrepreneurship.

TRENDS. HAPPENINGS. INSIGHTS

News & Events

June 2022 – Private Equity Investors in Primary Care

National Primary Care Transformation Summit

Moderator: John Selig

John moderated a panel discussing the enormous increase in investments in primary care by private equity firms and key benefits and concerns. Participants were Clayton, Dubilier & Rice, General Atlantic and Welsh, Carson, including Tom Scully, former head of CMS.

June 2022 - Valuation and Finance in Life Sciences

BIO International Convention - BD Executive Training Course

Faculty: John Selig

BD Executive Training, Valuation for Licensing & M&A

January 2022 – Private Equity Investors in Primary Care

First Annual PHA State of Population Health

Speaker: Rose Maljanian

Rose spoke about her top 5 issues for population health management heading into 2022 and what she believes are the top solution areas that will contribute to improving health, quality and affordability.

June 2021 - Valuation and Finance in Life Sciences

BIO International Convention - BD Executive Training Course

Faculty: John Selig

BD Executive Training, Valuation for Licensing & M&A

October 2020- Investing in Healthcare Services

Population Health Alliance

Panelist: Rose Maljanian

Rose joined an investor panel sponsored by Population Health Alliance on high stakes growth investments, acquisitions, IPOs and SPACs in the healthcare services space.

July 2020 - Demand for Digital Health Services

WellDoc Panel

Panelist: Rose Maljanian

Rose highlights industry trends and growing demand for digital health services in "Digital Health is Health: A Discussion on Remote Care, Reimbursement, & Real-World Results" webinar hosted by WellDoc.

June 2020 - Valuation and Finance in Life Sciences

BIO International Convention - BD Executive Training Course

Faculty: John Selig

BD Executive Training, Valuation for Licensing & M&A

Dec 2019 - M&A And Capital Raising For Life Sciences And Healthcare Companies

Everything You Always Wanted to Know But Were Afraid to Ask”, ShareVault webinar - Speaker John Selig

Nov 2019 - What Does The Investment Community See In Healthcare?

APG Colloquium - Speaker John Selig, Plenary

June 2019 - Valuation and Finance in Life Sciences

BIO International Convention - BD Executive Training Course

Faculty: John Selig

BD Executive Training, Valuation for Licensing & M&A

June 2018 - Valuation and Finance in Life Sciences

BIO International Convention - BD Executive Training Course

Faculty: John Selig

BD Executive Training, Valuation for Licensing & M&A

June 2017 - Valuation and Finance in Life Sciences

BIO International Convention - BD Executive Training Course

Faculty: Jeff Karan

BD Executive Training, Valuation for Licensing & M&A

June 2016 - Valuation and Finance in Life Sciences

BIO International Convention - BD Executive Training Course

Faculty: John Selig

BD Executive Training, Valuation for Licensing & M&A

June 2015 - Valuation and Finance in Life Sciences

BIO International Convention - BD Executive Training Course

Faculty: John Selig

BD Executive Training, Valuation for Licensing & M&A

2014 to Present - Advisory Board of Digital Health Fund

Speaker Jeff Karan and John Selig

Business Partnerships with the Following Organizations

Our Partners

The Founders of Launchpad Digital Health are on a mission to improve health in the world.

The Founders of Launchpad Digital Health are on a mission to improve health in the world. The best way for them to do this is by funding new great companies that can achieve that goal. Ted and Fred have spent their careers funding healthcare and technology companies to improve health. This continues as the driving reason for starting this digital health accelerator.

To augment this effort, the Founders are using 5% of their profits from Launchpad Digital Health to fund micro-lending to small healthcare businesses throughout the world. This enables many new health-related startup businesses with little access to capital to start and thrive. Partnering with Kiva, the largest, most successful microlending platform in the world, is the best way to do this.

This simple commitment from the Founders, Ted and Fred, can change the lives of millions.

To learn more about Launchpad Digital Health, click here.

ShareVault offers secure, cloud-based document sharing solutions, also known as virtual data rooms, that are frequently used by organizations of all types to securely share highly confidential documents with outside parties.

This simple commitment from the Founders, Ted and Fred, can change the lives of millions.

To learn more about Launchpad Digital Health, click here.

CHECK THE BACKGROUND OF THIS FIRM ON FINRA’S BROKERCHECK.

Let Our Experience Be Your Guide

Contact Us Today!

Click Here

Securities activities are conducted exclusively through WaveEdge Partners LLC, a registered broker-dealer and member of FINRA and SIPC. WaveEdge Capital LLC and WaveEdge Partners LLC are affiliated companies.

Privacy Policy | Cookie Policy (US)